drugset
drugset / Trial / NCT02556437

Efficacy and Safety of HyQvia (Immunoglobulin 10% With Recombinant Hyaluronidase) in Multifocal Motor Neuropathy (MMN)

NCT02556437 ↗

Phase 2 Completed 18 enrolled Johannes Jakobsen Baxter Healthcare Corporation · collab
RandomizedCrossoverSingle-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of HyQvia (Immunoglobulin 10% with recombinant hyaluronidase) with conventional subcutaneous immunoglobulin treatment in patients with Multifocal Motor Neuropathy (MMN).

Timeline

Start
2016-06
Primary completion
2018-05
Completion
2018-05

Drugs

EvaluationDrugModalityDoseRoute
Subject HYQVIA Protein / enzyme biologic 10 % Subcutaneous
Subject Subcutaneous immunoglobulin Protein / enzyme biologic 16 % Subcutaneous

Indications

multifocal motor neuropathy